Biologic therapies have become widely used but often cause cutaneous adverse effects. The authors discuss the cutaneous adverse effects of tumor necrosis factor (TNF) alpha inhibitors, epidermal growth factor receptor (EGFR) inhibitors, small-molecule tyrosine kinase inhibitors (TKIs), and cell surface-targeted monoclonal antibodies, including how to manage these reactions and when to refer to a dermatologist.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3949/ccjm.87a.19119 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!